Select Publications
Journal articles
2022, 'Effectively communicating comprehensive tumor genomic profiling results: Mitigating uncertainty for advanced cancer patients', Patient Education and Counseling, 105, pp. 452 - 459, http://dx.doi.org/10.1016/j.pec.2021.05.018
,2022, 'Rare germline variants in childhood cancer patients suspected of genetic predisposition to cancer', Genes Chromosomes and Cancer, 61, pp. 81 - 93, http://dx.doi.org/10.1002/gcc.23006
,2022, 'Value of whole-genome sequencing to Australian cancer patients and their first-degree relatives participating in a genomic sequencing study', Journal of Genetic Counseling, 31, pp. 96 - 108, http://dx.doi.org/10.1002/jgc4.1455
,2022, 'Clinical Response to Seribantumab, an Anti-Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an NRG1 Fusion', JCO PRECISION ONCOLOGY, 6, http://dx.doi.org/10.1200/PO.22.00263
,2022, 'Psychological Outcomes in Advanced Cancer Patients After Receiving Genomic Tumor Profiling Results', Health Psychology, 41, pp. 396 - 408, http://dx.doi.org/10.1037/hea0001181
,2021, 'ClinSV: clinical grade structural and copy number variant detection from whole genome sequencing data', Genome Medicine, 13, pp. 32, http://dx.doi.org/10.1186/s13073-021-00841-x
,2021, 'Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology', npj Precision Oncology, 5, pp. 58, http://dx.doi.org/10.1038/s41698-021-00194-z
,2021, 'Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions', Genome Biology, 22, pp. 109, http://dx.doi.org/10.1186/s13059-021-02315-0
,2021, 'Fear of cancer recurrence in patients undergoing germline genome sequencing', Supportive Care in Cancer, 29, pp. 7289 - 7297, http://dx.doi.org/10.1007/s00520-021-06311-9
,2021, 'Germline PALB2 variants and PARP inhibitors in endometrial cancer', JNCCN Journal of the National Comprehensive Cancer Network, 19, pp. 1212 - 1217, http://dx.doi.org/10.6004/jnccn.2021.7067
,2021, 'Longitudinal patterns in fear of cancer progression in patients with rare, advanced cancers undergoing comprehensive tumour genomic profiling', Psycho-Oncology, 30, pp. 1920 - 1929, http://dx.doi.org/10.1002/pon.5764
,2021, 'Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer', Leukemia, 35, pp. 3245 - 3256, http://dx.doi.org/10.1038/s41375-021-01246-w
,2021, 'The experiences and needs of australian medical oncologists in integrating comprehensive genomic profiling into clinical care: A nation-wide survey', Oncotarget, 12, pp. 2169 - 2176, http://dx.doi.org/10.18632/ONCOTARGET.28076
,2021, 'Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities', Cancer, 127, pp. 2934 - 2942, http://dx.doi.org/10.1002/cncr.33618
,2021, 'Does undertaking genome sequencing prompt actual and planned lifestyle-related behavior change in cancer patients and survivors? A qualitative study', Journal of Psychosocial Oncology Research and Practice, 3, pp. E059, http://dx.doi.org/10.1097/OR9.0000000000000059
,2021, 'Influence of lived experience on risk perception among women who received a breast cancer polygenic risk score: ‘Another piece of the pie’', Journal of Genetic Counseling, 30, pp. 849 - 860, http://dx.doi.org/10.1002/jgc4.1384
,2021, 'Family communication about genomic sequencing: A qualitative study with cancer patients and relatives', Patient Education and Counseling, 104, pp. 944 - 952, http://dx.doi.org/10.1016/j.pec.2020.10.022
,2021, 'PD-1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma', Cancer Reports, 4, http://dx.doi.org/10.1002/cnr2.1327
,2021, 'Germline RET variants underlie a subset of paediatric osteosarcoma', Journal of Medical Genetics, 58, pp. 20 - 24, http://dx.doi.org/10.1136/jmedgenet-2019-106734
,2021, 'Novel RET fusion RET-SEPTIN9 predicts response to selective RET inhibition with selpercatinib in malignant pheochromocytoma', JCO Precision Oncology, 5, pp. 1160 - 1165, http://dx.doi.org/10.1200/PO.21.00127
,2021, 'Disparities in Cancer Care: The Example of Sarcoma-In Search of Solutions for a Global Issue.', Am Soc Clin Oncol Educ Book, 41, pp. 1 - 7, http://dx.doi.org/10.1200/EDBK_320463
,2021, 'Heritable cancer risk in the genomic ERA', Pathology, 53, pp. S10 - S10, http://dx.doi.org/10.1016/j.pathol.2021.05.038
,2021, 'Streamlined use of protein structures in variant analysis', , http://dx.doi.org/10.1101/2021.09.10.459756
,2020, 'Author Correction: Diagnosis of fusion genes using targeted RNA sequencing (Nature Communications, (2019), 10, 1, (1388), 10.1038/s41467-019-09374-9)', Nature Communications, 11, pp. 1810, http://dx.doi.org/10.1038/s41467-020-15697-9
,2020, 'BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis', Journal of the National Cancer Institute, 112, pp. 1190 - 1203, http://dx.doi.org/10.1093/jnci/djaa070
,2020, 'The Medical Genome Reference Bank contains whole genome and phenotype data of 2570 healthy elderly', Nature Communications, 11, pp. 435, http://dx.doi.org/10.1038/s41467-019-14079-0
,2020, 'Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network', Annals of Oncology, 31, pp. 1506 - 1517, http://dx.doi.org/10.1016/j.annonc.2020.08.2232
,2020, 'Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer', Nature Medicine, 26, pp. 1742 - 1753, http://dx.doi.org/10.1038/s41591-020-1072-4
,2020, 'Cancer patients' views and understanding of genome sequencing: A qualitative study', Journal of Medical Genetics, 57, pp. 671 - 676, http://dx.doi.org/10.1136/jmedgenet-2019-106410
,2020, 'Advanced Cancer Patient Knowledge of and Attitudes towards Tumor Molecular Profiling', Translational Oncology, 13, pp. 100799, http://dx.doi.org/10.1016/j.tranon.2020.100799
,2020, 'Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours', Oncotarget, 11, pp. 2636 - 2646, http://dx.doi.org/10.18632/oncotarget.27659
,2020, 'A signal-seeking trial of olaparib and durvalumab in homologous repair-deficient tumors: A sub-study of the cancer molecular screening and therapeutics (MoST) program.', Journal of Clinical Oncology, 38, pp. 3073 - 3073, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3073
,2020, 'Genotype and phenotype correlation of common cancer predisposition syndromes in sarcoma cases.', Journal of Clinical Oncology, 38, pp. 1524 - 1524, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.1524
,2020, 'Return of results after somatic tumor mutation profiling in advanced cancer: Psychological impacts.', Journal of Clinical Oncology, 38, pp. 1541 - 1541, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.1541
,2020, 'Assessment of the Value of Tumor Variation Profiling Perceived by Patients with Cancer', JAMA Network Open, 3, pp. e204721, http://dx.doi.org/10.1001/jamanetworkopen.2020.4721
,2020, 'Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients with Osteosarcoma', JAMA Oncology, 6, pp. 724 - 734, http://dx.doi.org/10.1001/jamaoncol.2020.0197
,2020, 'MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer', Science
,2020, 'Who should access germline genome sequencing? A mixed methods study of patient views', Clinical Genetics, 97, pp. 329 - 337, http://dx.doi.org/10.1111/cge.13664
,2020, 'Penetrance of different cancer types in families with Li-Fraumeni syndrome: A validation study using multicenter cohorts', Cancer Research, 80, pp. 354 - 360, http://dx.doi.org/10.1158/0008-5472.CAN-19-0728
,2020, 'Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas', OncoImmunology, 9, pp. 1747340, http://dx.doi.org/10.1080/2162402X.2020.1747340
,2020, 'Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology', , http://dx.doi.org/10.1101/2020.12.18.20248521
,2020, 'Heritable cancer risk in the genomic era', Pathology, 52, pp. S28 - S29, http://dx.doi.org/10.1016/j.pathol.2020.01.118
,2019, 'Diagnosis of fusion genes using targeted RNA sequencing', Nature Communications, 10, pp. 1388, http://dx.doi.org/10.1038/s41467-019-09374-9
,2019, 'Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas', Modern Pathology, 32, pp. 1772 - 1785, http://dx.doi.org/10.1038/s41379-019-0312-y
,2019, 'Infiltrating myeloid cells drive osteosarcoma progression via GRM4 regulation of IL23', Cancer Discovery, 9, pp. 1511 - 1519, http://dx.doi.org/10.1158/2159-8290.CD-19-0154
,2019, 'Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial', The Lancet, 394, pp. 478 - 487, http://dx.doi.org/10.1016/S0140-6736(19)30764-0
,2019, 'Patient perspectives on molecular tumor profiling: "why wouldn't you?"', BMC Cancer, 19, pp. 753, http://dx.doi.org/10.1186/s12885-019-5920-x
,2019, 'A quantitative model to predict pathogenicity of missense variants in the TP53 gene', Human Mutation, 40, pp. 788 - 800, http://dx.doi.org/10.1002/humu.23739
,2019, 'Author Correction: Therapeutic implications of germline genetic findings in cancer (Nature Reviews Clinical Oncology, (2019), 16, 6, (386-396), 10.1038/s41571-019-0179-3)', Nature Reviews Clinical Oncology, 16, pp. 397, http://dx.doi.org/10.1038/s41571-019-0212-6
,2019, 'Therapeutic implications of germline genetic findings in cancer', Nature Reviews Clinical Oncology, 16, pp. 386 - 396, http://dx.doi.org/10.1038/s41571-019-0179-3
,